Developer docs
API playgroundTry for free, no card

Search company profiles

Verantos

Full company profile

uuid0000lwi

Namestring
Verantos
Legal namestring
Verantos, Inc.
Websiteurl
verantos.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Verantos, Inc. is a privately held health technology company founded in 2013 and headquartered in Menlo Park, California. The company generates high-validity real-world evidence (RWE) for life sciences organizations using a proprietary AI-based deep phenotyping platform that extracts structured and unstructured patient information — including clinical narrative typically absent from coded EHR fields — to produce clinically rich, traceable data sets. Its product portfolio centers on the Verantos Evidence Platform (comprising a federated research network, AI engine, data processing layer, and research analytics), a portfolio of disease-specific Pragmatic Registries across cardiovascular, neuroscience, respiratory, and gastrointestinal therapeutic areas, and custom Observational Research services. Data is normalized and delivered in OMOP CDM format, and the company reports access to over 50 million patients across 29 states through partnerships with academic medical centers and community health systems.

Verantos serves primarily top-tier pharmaceutical and biotechnology firms, with named engagements including Amgen and an undisclosed set of top-10 life sciences customers. Secondary customers include healthcare providers and academic medical centers participating in the research network, payers and HTA bodies for market access evidence, and regulatory agencies (notably the FDA, which selected Verantos as a demonstration project for regulatory guidance on data quality). The business model combines subscription-based access to high-validity RWE data and Pragmatic Registry datasets with project-based observational research services, priced on negotiated annual contracts.

The company is led by CEO Dan Riskin and an executive team including President Anand Shroff, VP Engineering, and VP Marketing. To date, disclosed capital inflows are limited to National Science Foundation grants (a $225K award in 2018 and $1.2M in 2020) for RWE outcomes research; broader venture funding history is not disclosed in the input. Verantos has been recognized across multiple years on the Deloitte Technology Fast 500 and Inc. 5000, was named among the Top 50 Healthcare Technology Companies of 2025, and was recognized as a leader among Top AI Healthcare Companies in 2026. Its science has been validated and funded by NIH, NSF, and FDA, distinguishing it credential-wise within the RWE vendor landscape.

Short descriptiontext

Verantos is a private health technology company that uses AI-based deep phenotyping to generate high-validity real-world evidence from structured and unstructured EHR data, serving top-tier pharmaceutical and biotechnology firms with subscription registries and custom observational research.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
real-world evidence, clinical data analytics, pharmaceutical research services, health data platform, EHR phenotyping
Industry5 codes
PRIMARYHLACAOAM
Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAIAJ
Real-World Data (RWD) Platforms & Clinical Data Curation
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare Data Platforms, Warehousing & Governance
SECONDARYBPAHALAN
Healthcare Outcomes & Real-World Evidence (RWE) Analytics
SECONDARYHLAGAJAF
Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAI
Real-World Evidence (RWE) & HEOR for Development
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Real-World Evidence Platform
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1High-validity RWE Data and Analytics Services
TypeSubscription Recurring
Description

Subscription-based access to high-quality real-world data and evidence generation services for life sciences companies. Services span clinical development, market access, medical affairs, pharmacovigilance, and regulatory initiatives across therapeutic areas.

verantos.com
2Pragmatic Registry Subscriptions
TypeSubscription Recurring
Description

Disease-specific registry subscriptions providing indication-specific data sets with configurable variables and endpoints. Registries available for cardiovascular, neuroscience, respiratory, and gastrointestinal therapeutic areas.

verantos.com
3Observational Research Studies
TypeProfessional Services
Description

Custom observational research generating high-validity RWE for life sciences companies' longitudinal studies with deep phenotyping to support inclusion/exclusion criteria, endpoints, and outcomes.

verantos.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
Pricing details2 tiers
1Enterprise-customized subscription and service packages
ModelSubscriptionBilling cadenceAnnual
Notes

Pricing is negotiated based on therapeutic area focus, data scope, registry access requirements, and study complexity. No public pricing tiers listed.

verantos.com
2Pragmatic Registry access by therapeutic area
ModelSubscriptionBilling cadenceAnnual
Notes

Disease-specific registries (cardiovascular, neuroscience, respiratory, gastrointestinal) available for subscription with configurable variables and endpoints.

verantos.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1Pragmatic Registry
Description

Disease-specific registries of study subjects generated from routinely collected, real-world data, enabling life sciences companies to subscribe to clinically rich, high-quality data sets.

verantos.com
+2 more records
Core offering1 text field

Verantos generates high-validity real-world evidence (RWE) at scale from complete patient records using proprietary AI-based deep phenotyping technology and natural language processing applied to structured and unstructured EHR data. The company offers the Verantos Evidence Platform, disease-specific Pragmatic Registries (cardiovascular, neuroscience, respiratory, gastrointestinal), and Observational Research services to life sciences organizations for clinical development, market access, pharmacovigilance, and regulatory submissions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 94.1% F1 score in heart failure phenotyping vs 49.0% for traditional structured query approaches
+5 more records
Product overview1 text field

Verantos is a real-world evidence company offering a platform-plus-products architecture centered on the Verantos Evidence Platform. The platform uses proprietary deep phenotyping technology and AI to generate high-validity RWE from complete patient records including unstructured EHR clinical narrative. The product portfolio includes Pragmatic Registries (disease-specific registries for cardiovascular, neuroscience, respiratory, and gastrointestinal areas), Observational Research services, and access to the Verantos Research Network (federated data network of 50+ million patients across 29 states). Data is normalized and delivered in OMOP CDM format.

Product and service4 records
1Verantos Evidence Platform
2Pragmatic Registry
CategoryRegistry / Data Subscription
Description

Disease-specific registries of study subjects generated from routinely collected real-world data, providing clinically rich, high-quality data sets representing the patient journey. Available for cardiovascular, neuroscience, respiratory, and gastrointestinal therapeutic areas, with data normalized and delivered in standardized OMOP CDM format. Specific variants include Cardiovascular (heart failure, stroke, pulmonary hypertension), Neuroscience (Alzheimer's, Parkinson's, dementia, depression, schizophrenia, migraine), Respiratory (asthma, COPD, interstitial lung disease, idiopathic pulmonary fibrosis), and Gastrointestinal (ulcerative colitis, Crohn's disease, celiac disease, primary biliary cholangitis).

3Observational Research
4Verantos Research Network
Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborative research partner on multiple high-validity RWE studies. Co-authored heart failure phenotyping manuscript published in BMJ Open, migraine RWE publications, and asthma validation studies presented at CHEST 2023. Multiple commercial engagements as validated customer.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Life sciences partner visible in partner logo section on homepage, indicating collaborative relationship for RWE evidence generation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading academic medical centers as research partners in the Verantos Research Network, providing access to structured and unstructured EHR data for evidence generation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Community health systems as research network partners enabling geographic distribution across 29 states for generalizability and external validity.

5Disease Registries
Strategic tierSupportingTypeTechnology or Integration
Description

Registry partners contributing to the federated data network alongside claims aggregators for complete study subject views.

verantos.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Selected as FDA demonstration project to enable regulatory guidance on data quality. Verantos helped shape policy on use of advanced clinical data and technologies through Congressional testimony on 21st Century Cures Initiative.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Flatiron Health provides real-world evidence derived from EHR and oncology data for life sciences, very similar to Verantos' RWE-from-EHR model. Both serve pharma/biotech for clinical development and regulatory evidence, though Flatiron is oncology-specialized and part of Roche.

TypeBroad incumbent
Description

IQVIA offers extensive RWE, HEOR, and real-world data services to life sciences globally. Overlaps with Verantos across observational research, registry, and regulatory-grade RWE, but at vastly greater scale and as part of a broad CRO/data portfolio.

TypeBroad incumbent
Description

Optum's Life Sciences division delivers real-world data and evidence to pharma, drawing on claims and EHR assets. Competes with Verantos in RWE for clinical development and market access, but as part of a much larger payer/provider data conglomerate.

4Tempus AI
TypeDirect peer
Description

Tempus combines molecular and clinical data with AI to generate real-world evidence for life sciences, including oncology and increasingly other therapeutic areas. Comparable to Verantos in AI-driven RWE for pharma, with broader multi-omic and clinical-trial offerings.

TypeDirect peer
Description

Aetion provides a regulatory-grade real-world evidence platform used by pharma, payers, and regulators including FDA collaborations. Highly comparable to Verantos in targeting regulatory-grade RWE for life sciences decisions.

TypeEmerging player
Description

Truveta aggregates de-identified EHR data from large US health systems to deliver real-world evidence to life sciences. Comparable in using health-system-sourced EHR data for pharma RWE, with a federated member-system model similar to Verantos' Research Network.

TypeDirect peer
Description

TriNetX operates a global federated health-research network providing real-world data and analytics for clinical trial and observational research. Comparable to Verantos' Research Network and observational research offerings, serving pharma across therapeutic areas.

TypeBroad incumbent
Description

Cognizant's life sciences services include real-world evidence, HEOR, and clinical data analytics through its broader IT services portfolio. Competes indirectly with Verantos for pharma RWE engagements, especially for large enterprise transformations.

TypeBroad incumbent
Description

Syneos Health offers real-world evidence and observational research services alongside its CRO operations. Comparable to Verantos in observational RWE delivery, though as part of a full clinical and commercial services portfolio for life sciences.

TypeEmerging player
Description

Atropos Health generates real-world evidence from EHR data using AI to answer clinical and research questions for providers and life sciences. Comparable to Verantos in AI-driven RWE from EHR, but with a broader provider-and-pharma footprint and federated data approach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Verantos

Real-World Evidence Platformverantos.com

Verantos is a private health technology company that uses AI-based deep phenotyping to generate high-validity real-world evidence from structured and unstructured EHR data, serving top-tier pharmaceutical and biotechnology firms with subscription registries and custom observational research.

What Verantos does

Verantos, Inc. is a privately held health technology company founded in 2013 and headquartered in Menlo Park, California. The company generates high-validity real-world evidence (RWE) for life sciences organizations using a proprietary AI-based deep phenotyping platform that extracts structured and unstructured patient information — including clinical narrative typically absent from coded EHR fields — to produce clinically rich, traceable data sets. Its product portfolio centers on the Verantos Evidence Platform (comprising a federated research network, AI engine, data processing layer, and research analytics), a portfolio of disease-specific Pragmatic Registries across cardiovascular, neuroscience, respiratory, and gastrointestinal therapeutic areas, and custom Observational Research services. Data is normalized and delivered in OMOP CDM format, and the company reports access to over 50 million patients across 29 states through partnerships with academic medical centers and community health systems.

Verantos serves primarily top-tier pharmaceutical and biotechnology firms, with named engagements including Amgen and an undisclosed set of top-10 life sciences customers. Secondary customers include healthcare providers and academic medical centers participating in the research network, payers and HTA bodies for market access evidence, and regulatory agencies (notably the FDA, which selected Verantos as a demonstration project for regulatory guidance on data quality). The business model combines subscription-based access to high-validity RWE data and Pragmatic Registry datasets with project-based observational research services, priced on negotiated annual contracts.

The company is led by CEO Dan Riskin and an executive team including President Anand Shroff, VP Engineering, and VP Marketing. To date, disclosed capital inflows are limited to National Science Foundation grants (a $225K award in 2018 and $1.2M in 2020) for RWE outcomes research; broader venture funding history is not disclosed in the input. Verantos has been recognized across multiple years on the Deloitte Technology Fast 500 and Inc. 5000, was named among the Top 50 Healthcare Technology Companies of 2025, and was recognized as a leader among Top AI Healthcare Companies in 2026. Its science has been validated and funded by NIH, NSF, and FDA, distinguishing it credential-wise within the RWE vendor landscape.

Verantos firmographics

Firmographics
Name
Verantos
Legal name
Verantos, Inc.
Website
https://verantos.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Short description
Verantos is a private health technology company that uses AI-based deep phenotyping to generate high-validity real-world evidence from structured and unstructured EHR data, serving top-tier pharmaceutical and biotechnology firms with subscription registries and custom observational research.
Ownership category
akta.pro rank

Verantos industry classification

Industry
Product category
Real-World Evidence Platform
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLACAOAM
Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAIAJ
Real-World Data (RWD) Platforms & Clinical Data Curation
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare Data Platforms, Warehousing & Governance
SECONDARYBPAHALAN
Healthcare Outcomes & Real-World Evidence (RWE) Analytics
SECONDARYHLAGAJAF
Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAI
Real-World Evidence (RWE) & HEOR for Development
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Real-world evidence
  • Clinical data analytics
  • Pharmaceutical research services
  • Health data platform
  • EHR phenotyping

Where Verantos is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Verantos business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. High-validity RWE Data and Analytics Services: Subscription-based access to high-quality real-world data and evidence generation services for life sciences companies. Services span clinical development, market access, medical affairs, pharmacovigilance, and regulatory initiatives across therapeutic areas.
  2. Pragmatic Registry Subscriptions: Disease-specific registry subscriptions providing indication-specific data sets with configurable variables and endpoints. Registries available for cardiovascular, neuroscience, respiratory, and gastrointestinal therapeutic areas.
  3. Observational Research Studies: Custom observational research generating high-validity RWE for life sciences companies' longitudinal studies with deep phenotyping to support inclusion/exclusion criteria, endpoints, and outcomes.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise-customized subscription and service packages
SubscriptionAnnualPragmatic Registry access by therapeutic area

Go-to-market motion2 records

Distribution channels2 records

Marketing channels8 records

Verantos product offering

Product offering

Core offering

Verantos generates high-validity real-world evidence (RWE) at scale from complete patient records using proprietary AI-based deep phenotyping technology and natural language processing applied to structured and unstructured EHR data. The company offers the Verantos Evidence Platform, disease-specific Pragmatic Registries (cardiovascular, neuroscience, respiratory, gastrointestinal), and Observational Research services to life sciences organizations for clinical development, market access, pharmacovigilance, and regulatory submissions.

Product overview

Verantos is a real-world evidence company offering a platform-plus-products architecture centered on the Verantos Evidence Platform. The platform uses proprietary deep phenotyping technology and AI to generate high-validity RWE from complete patient records including unstructured EHR clinical narrative. The product portfolio includes Pragmatic Registries (disease-specific registries for cardiovascular, neuroscience, respiratory, and gastrointestinal areas), Observational Research services, and access to the Verantos Research Network (federated data network of 50+ million patients across 29 states). Data is normalized and delivered in OMOP CDM format.

Differentiator

Problem solved

Functional benefit

Brands

  • Pragmatic Registry: Disease-specific registries of study subjects generated from routinely collected, real-world data, enabling life sciences companies to subscribe to clinically rich, high-quality data sets.
  • Verantos Evidence Platform
  • Verantos Research Network

Products and services

  • Verantos Evidence Platform
  • Pragmatic Registry Disease-specific registries of study subjects generated from routinely collected real-world data, providing clinically rich, high-quality data sets representing the patient journey. Available for cardiovascular, neuroscience, respiratory, and gastrointestinal therapeutic areas, with data normalized and delivered in standardized OMOP CDM format. Specific variants include Cardiovascular (heart failure, stroke, pulmonary hypertension), Neuroscience (Alzheimer's, Parkinson's, dementia, depression, schizophrenia, migraine), Respiratory (asthma, COPD, interstitial lung disease, idiopathic pulmonary fibrosis), and Gastrointestinal (ulcerative colitis, Crohn's disease, celiac disease, primary biliary cholangitis).
  • Observational Research
  • Verantos Research Network

Quantifiable outcome

  • 94.1% F1 score in heart failure phenotyping vs 49.0% for traditional structured query approaches
  • +5 more outcomes

Companies that use Verantos

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Verantos technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature8 records

Verantos partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and supporting.

  • AmgencoreStrategic or Co-development PartnerCollaborative research partner on multiple high-validity RWE studies. Co-authored heart failure phenotyping manuscript published in BMJ Open, migraine RWE publications, and asthma validation studies presented at CHEST 2023. Multiple commercial engagements as validated customer.
  • BayercoreStrategic or Co-development PartnerLife sciences partner visible in partner logo section on homepage, indicating collaborative relationship for RWE evidence generation.
  • Academic Medical Centers (unnamed)coreStrategic or Co-development PartnerLeading academic medical centers as research partners in the Verantos Research Network, providing access to structured and unstructured EHR data for evidence generation.
  • Community Health Systems (unnamed)coreStrategic or Co-development PartnerCommunity health systems as research network partners enabling geographic distribution across 29 states for generalizability and external validity.
  • Disease RegistriessupportingTechnology or IntegrationRegistry partners contributing to the federated data network alongside claims aggregators for complete study subject views.
  • Food and Drug Administration (FDA)coreStrategic or Co-development PartnerSelected as FDA demonstration project to enable regulatory guidance on data quality. Verantos helped shape policy on use of advanced clinical data and technologies through Congressional testimony on 21st Century Cures Initiative.

Scale indicators13 records

Recent moves6 records

Expansion highlights5 records

Verantos competitors and assessment

Company assessment

Direct peers

  • Flatiron Health: Flatiron Health provides real-world evidence derived from EHR and oncology data for life sciences, very similar to Verantos' RWE-from-EHR model. Both serve pharma/biotech for clinical development and regulatory evidence, though Flatiron is oncology-specialized and part of Roche.
  • Tempus AI: Tempus combines molecular and clinical data with AI to generate real-world evidence for life sciences, including oncology and increasingly other therapeutic areas. Comparable to Verantos in AI-driven RWE for pharma, with broader multi-omic and clinical-trial offerings.
  • Aetion: Aetion provides a regulatory-grade real-world evidence platform used by pharma, payers, and regulators including FDA collaborations. Highly comparable to Verantos in targeting regulatory-grade RWE for life sciences decisions.
  • TriNetX: TriNetX operates a global federated health-research network providing real-world data and analytics for clinical trial and observational research. Comparable to Verantos' Research Network and observational research offerings, serving pharma across therapeutic areas.

Broad incumbents

  • IQVIA (Real-World Solutions): IQVIA offers extensive RWE, HEOR, and real-world data services to life sciences globally. Overlaps with Verantos across observational research, registry, and regulatory-grade RWE, but at vastly greater scale and as part of a broad CRO/data portfolio.
  • Optum (UnitedHealth Group): Optum's Life Sciences division delivers real-world data and evidence to pharma, drawing on claims and EHR assets. Competes with Verantos in RWE for clinical development and market access, but as part of a much larger payer/provider data conglomerate.
  • Cognizant (RWE / TriZetto): Cognizant's life sciences services include real-world evidence, HEOR, and clinical data analytics through its broader IT services portfolio. Competes indirectly with Verantos for pharma RWE engagements, especially for large enterprise transformations.
  • Syneos Health (now part of Elliott/Patient Square): Syneos Health offers real-world evidence and observational research services alongside its CRO operations. Comparable to Verantos in observational RWE delivery, though as part of a full clinical and commercial services portfolio for life sciences.

Emerging players

  • Truveta: Truveta aggregates de-identified EHR data from large US health systems to deliver real-world evidence to life sciences. Comparable in using health-system-sourced EHR data for pharma RWE, with a federated member-system model similar to Verantos' Research Network.
  • Atropos Health: Atropos Health generates real-world evidence from EHR data using AI to answer clinical and research questions for providers and life sciences. Comparable to Verantos in AI-driven RWE from EHR, but with a broader provider-and-pharma footprint and federated data approach.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Verantos social profiles

Digital presence

Verantos financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Verantos leadership team

Management profile

Number of profiles

Profiles4 records

Verantos funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Verantos M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Verantos

What does Verantos do?

Verantos generates high-validity real-world evidence (RWE) at scale from complete patient records using proprietary AI-based deep phenotyping technology and natural language processing applied to structured and unstructured EHR data. The company offers the Verantos Evidence Platform, disease-specific Pragmatic Registries (cardiovascular, neuroscience, respiratory, gastrointestinal), and Observational Research services to life sciences organizations for clinical development, market access, pharmacovigilance, and regulatory submissions.

Is Verantos a public or private company?

Verantos is a private company. It is classified as venture growth investor backed and is currently operating.

When was Verantos founded?

Verantos was founded in 2013. It employs 51 to 100 people.

Where is Verantos based?

Verantos is headquartered in Menlo Park, United States, in the North America region.

How does Verantos make money?

Three revenue lines are on record. High-validity RWE Data and Analytics Services are the primary driver. The others are pragmatic Registry Subscriptions and observational Research Studies.

Who are Verantos's main competitors?

Direct peers on record are Flatiron Health, Tempus AI, Aetion and TriNetX. Broad incumbents are IQVIA (Real-World Solutions), Optum (UnitedHealth Group), Cognizant (RWE / TriZetto) and Syneos Health (now part of Elliott/Patient Square). Emerging players are Truveta and Atropos Health.

Does Verantos have an API?

No public API is recorded for Verantos.

What industry is Verantos in?

Verantos's product category is Real-World Evidence Platform. Its primary akta.pro industry code is HLACAOAM, Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms, with a secondary code of HLACAIAJ, Real-World Data (RWD) Platforms & Clinical Data Curation. Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogVerantos Named to Inc. 5000 List for the Fifth Consecutive YearVerantos has been named to the Inc. 5000 Honor Roll for the fifth consecutive year, ranking No. 2961 on the list of America's fastest-growing private companies. This recognition highlights the company's sustained revenue growth since 2018 and reflects continued market demand for its high-validity real-world evidence solutions in the life sciences sector.FinancialContent Business PageVerantos Named to Inc. 5000 List for the Fifth Consecutive YearVerantos has achieved Honor Roll status by being ranked on the Inc. 5000 list for the fifth consecutive year, placing No. 2961 in 2026. This distinction is given to fewer than 10% of companies that have been featured multiple times, highlighting Verantos' sustained growth in the life sciences sector since 2018. The Inc. 5000 list reflects the success of companies that have significantly contributed to job creation and economic growth in the U.S.Business Wire BlogVerantos Ranked Number 444th Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™Verantos, a real-world evidence company, announced it ranked 444th on the 2025 Deloitte Technology Fast 500™ list, a ranking of the 500 fastest-growing technology companies in North America. The company was notably the only real-world evidence-focused firm included on the list, with eligibility requiring minimum revenue thresholds and at least 50% growth from 2021 to 2024. The ranking highlights companies with proprietary intellectual property or technology contributing significantly to operating revenues.AInvestThe AI Healthcare Revolution: Why Now is the Time to Invest in Undervalued StartupsThe AI healthcare market is projected to grow from $26.69 billion in 2024 to $613.81 billion by 2034. Four undervalued startups—XpertDox, Verantos, Generate:Biomedicines, and MDI Health—are highlighted for their IP and cost-saving potential. The article urges early investment as adoption accelerates.Business Wire BlogVerantos Ranked Number 319 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™Verantos ranked 319th on the 2024 Deloitte Technology Fast 500, the fastest-growing North American tech companies. The company grew 368% over the period, and CEO Dan Riskin attributed the growth to rising demand for high-validity real-world evidence in life sciences.Business Wire BlogVerantos Ranked Number 319 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™Verantos ranked 319 on the Deloitte Technology Fast 500, growing 368% from 2020 to 2023. The company is the only real-world evidence firm on the list for the second consecutive year, citing demand from life sciences for high-validity data.PR NewswireDistinguished experts join Verantos inflammatory bowel disease advisory panelVerantos, a high-validity real-world evidence company, announced that Dr. Adam S. Cheifetz of Beth Israel Deaconess Medical Center and Dr. Gil Y. Melmed of Cedars-Sinai Medicine have joined its inflammatory bowel disease advisory panel. The two experts will provide input on Verantos' Inflammatory Bowel Disease Pragmatic Registry, which generates disease-specific registries from routinely collected real-world data for subscription by life sciences companies. Both doctors are recognized leaders in IBD treatment and research, with extensive publication records and leadership positions at their respective institutions.PR NewswireVerantos launches Inflammatory Bowel Disease Pragmatic Registry to support high-validity real-world evidence generation in ulcerative colitis, Crohn's diseaseVerantos, a company specializing in high-validity real-world evidence, announced the launch of its Inflammatory Bowel Disease Pragmatic Registry containing 3 billion data points on ulcerative colitis and Crohn's disease patients. The registry uses artificial intelligence to combine structured and unstructured data from electronic health records with claims and mortality data to provide disease severity, treatment, symptom control, and clinical outcomes data. It is already in use by top biopharma companies and enables researchers to create trial- and label-similar cohorts for accelerating advanced therapies for inflammatory bowel disease.PR NewswireVerantos Announces Partnership with CuriMeta to Advance High-Validity, Real-World EvidenceVerantos, a leader in high-validity real-world evidence at scale, has partnered with CuriMeta to initially add de-identified data from 7 million patients to the Verantos Research Network, enhancing the quality and breadth of real-world health data available to life sciences organizations. CuriMeta's initial data collaborators include BJC HealthCare and Washington University School of Medicine in St. Louis. The partnership aims to accelerate life sciences research by providing high-quality patient care data to train AI models for disease-specific insights and pragmatic registries.